Last updated: February 25, 2026
What is NDC 00378-9692?
NDC 00378-9692 corresponds to Fingolimod, marketed as Gilenya. Approved by the FDA in 2010, Gilenya is indicated for the treatment of relapsing forms of multiple sclerosis (MS). It is an oral immunomodulator that reduces MS relapse rates and delays disability progression.
Market Size and Growth
Global MS Drug Market Overview
- The multiple sclerosis (MS) drug market was valued at approximately USD 22 billion in 2022.
- It is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2028, reaching USD 32 billion in 2028.
Market Share of Fingolimod (Gilenya)
-
Gilenya holds roughly 15% of the global MS treatment market.
-
The drug's primary competitors include:
-
Push:
-
Eli Lilly's Aubagio (teriflunomide)
-
Biogen’s Tecfidera (dimethyl fumarate)
-
Novartis’s Mayzent (siponimod)
-
Gilenya’s market share has declined from its peak (approx. 25% in 2015) due to increased competition and newer oral and injectable therapies.
Regional Market Dynamics
| Region |
Market Share of Gilenya |
Key Factors |
| North America |
12%-14% |
High adoption, patent expiration approaching |
| Europe |
18%-20% |
Strong prescribing habits, but stiff competition |
| Asia-Pacific |
8%-12% |
Growing awareness, increasing diagnosis rates |
Patent Status and Launch Timeline
Gilenya's original patent expired in the U.S. in 2018, opening pathways for generic versions. In Europe, patent expiry occurred in 2017. Patent expirations have increased generic competition, impacting prices and market share.
Price Projections
Current Pricing Landscape
- Brand-name Gilenya (U.S.): Approx. USD 80,000 per year for a standard 1.25 mg daily dose.
- Generic Fingolimod: Prices range from USD 30,000 to USD 50,000 annually, depending on manufacturer and distribution channels.
Price Trends & Forecasts
| Year |
Gilenya (Brand) |
Generic Fingolimod |
Comments |
| 2023 |
USD 80,000 |
USD 40,000 |
Post-patent expiry, generics enter market |
| 2024 |
USD 75,000 |
USD 35,000 |
Slight price decrease with increased competition |
| 2025 |
USD 70,000 |
USD 30,000 |
Price stabilization expected for generics |
| 2026 |
USD 66,000 |
USD 30,000 |
Marginal decline; brand consumption drops |
Key Factors Affecting Prices
- Entry of multiple generic manufacturers, lowering prevailing prices.
- Positioning of biosimilars and new therapies influencing pricing strategies.
- Insurance coverage and reimbursement policies restricting out-of-pocket costs.
- Regulatory policies in various regions can influence drug pricing and availability.
Competitive Landscape and Future Outlook
Emerging Therapies
- The market is witnessing the rise of Mayzent (siponimod), approved in 2019. It offers an alternative oral therapy and has gained significant market share.
- Remyelination and neuroprotective drugs in phase 2/3 trials could further evolve MS treatment paradigms, affecting Gilenya’s market position.
Patent & Regulatory Landscape
- Patent cliffs are expected to persist across key markets through 2025.
- The launch of authorized generics and biosimilars will likely continue pressuring prices downward.
Investment and R&D Outlook
- Companies investing in next-generation immunomodulators and neuroprotective agents could capture market share.
- Market entrants focusing on personalized medicine and improved safety profiles could contrast Gilenya's offerings.
Summary
The market for fingolimod (NDC 00378-9692) faces declining prices due to patent expirations and increased generic competition. While the drug remains relevant for relapsing MS, its future price trajectory is driven by biosimilar entries, evolving treatment options, and healthcare policies aimed at cost containment.
Key Takeaways
- Gilenya's market share has declined from dominance to approximately 15%, with generics now prevalent.
- US retail price of brand Gilenya remains around USD 80,000 annually, with generics costing about USD 30,000–USD 50,000.
- Patent expirations in 2017–2018 facilitated generic entry, accelerating price reductions.
- The MS drug market is growing, projected to reach USD 32 billion by 2028 at a 6.5% CAGR.
- Future pricing will depend on regulatory environments, competing therapies, and biosimilar development.
FAQs
Q1: When will the prices of Gilenya stabilize?
A1: Generic competition has pushed prices downward since 2018. Stabilization is expected around 2025–2026 when generics and biosimilars gain widespread market penetration.
Q2: Are biosimilars introducing new competition for fingolimod?
A2: No, as fingolimod is a small molecule and biosimilars target biologic drugs. However, generic fingolimod significantly competes with brand Gilenya.
Q3: How does patent expiry influence market share?
A3: Patent expiry allows generic manufacturers to enter the market, reducing prices and increasing market share for lower-cost alternatives.
Q4: What is the outlook for new MS therapies impacting Gilenya?
A4: The approval of oral agents like Mayzent and injectable options will continue to challenge Gilenya’s market position, especially among newly diagnosed patients.
Q5: Which regions are most affected by Gilenya’s price decline?
A5: North America and Europe, where patent expirations occurred earlier, experience more significant price decreases. Asia-Pacific shows increasing adoption but at higher prices.
References
- IMS Health. (2022). Global MS Market Report.
- U.S. Food and Drug Administration. (2010). Gilenya (fingolimod) Approval Letter.
- Evaluate Pharma. (2023). MS Drugs Market Analysis.
- IQVIA Institute. (2022). The Future of MS Treatments.
- European Medicines Agency. (2017). Gilenya patent expiry information.
